Fundamentals-based quality & risk · not a recommendation
Nath Bio-Genes (India) Ltd scores 58/100 (Watch) on the Orion Score — weak business quality (45), moderate growth (68), moderate balance-sheet safety (59) and cheap valuation (84). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
41/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q4 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q4 2026 | ₹51.59 | ₹-0.01 | 6.7% | ₹-0.79 |
| Q3 2026 | ₹65.96 | ₹1.6 | 3.9% | ₹0.84 |
| Q2 2026 | ₹43.85 | ₹2.75 | 11.7% | ₹1.40 |
| Q1 2026 | ₹283.7 | ₹37.28 | 13.2% | ₹19.58 |
| Q4 2025 | ₹51.97 | ₹1.48 | -1.8% | ₹0.42 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2026 | ₹445.1 | ₹41.63 | ₹66.26 | 10.9% |
| FY 2025 | ₹364.91 | ₹38.6 | ₹54.34 | 12.6% |
| FY 2024 | ₹332.62 | ₹39.62 | ₹56.72 | 14.1% |
| FY 2023 | ₹301.36 | ₹35.01 | ₹51.76 | 15.3% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| NATHBIOGEN ★ | ₹322 Cr | 8.07 | 6.90% | 6.29% | 0.20x | 6.69% |
| HINDUNILVR | ₹4,98,466 Cr | 46.95 | 21.37% | 21.60% | 0.03x | 21.55% |
| BRITANNIA | ₹1,30,370 Cr | 51.47 | 57.77% | 53.31% | 0.27x | 16.38% |
| COLPAL | ₹55,550 Cr | 40.99 | 103.69% | 81.59% | 0.03x | 29.98% |
| AWL | ₹24,400 Cr | 23.44 | 15.16% | 10.52% | 0.11x | 1.84% |
| CCL | ₹15,885 Cr | 41.00 | 20.46% | 18.00% | 0.56x | 12.36% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹1,026.21 | ₹880.23 | ₹792.8 | ₹739.49 |
| Equity | ₹644.39 | ₹609.92 | ₹573.17 | ₹541.93 |
| Total Debt | ₹122.5 | ₹110.35 | ₹105.21 | ₹92.96 |
| Cash | ₹88.53 | ₹77.13 | ₹37.99 | ₹4.18 |
| Net Debt | ₹33.97 | ₹33.21 | ₹67.22 | ₹88.78 |
| Working Capital | ₹324.71 | ₹309.22 | ₹303.4 | ₹273.47 |
Q1 FY2027
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q1 FY2027 | 61.39% ↑ | 0% ↓ | 0% ↓ | 38.61% ↓ |
| Q3 FY2026 | 45.59% | 0.31% ↓ | 0.01% ↓ | 54.08% ↑ |
| Q2 FY2026 | 45.59% | 0.32% ↓ | 0.76% ↓ | 53.31% ↑ |
| Q1 FY2026 | 45.59% | 0.41% ↑ | 2.25% ↓ | 51.73% ↑ |
| Q4 FY2025 | 45.59% | 0.21% ↑ | 3.94% ↓ | 50.24% ↑ |
| Q3 FY2025 | 45.59% | 0.19% ↑ | 4.37% | 49.83% |
| Q2 FY2025 | 45.59% | 0.18% ↓ | 4.37% | 49.83% ↑ |
| Q1 FY2025 | 45.59% | 0.21% | 4.37% | 49.8% |
No recent corporate actions
Ask: "Is Nath Bio-Genes (India) Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.
Nath Bio-Genes (India) Ltd is listed on the NSE under the Fast Moving Consumer Goods sector, Other Agricultural Products industry. ISIN: INE448G01010. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.